Related Experiment Videos
Hycanthone and its congeners as bacterial mutagens
Journal of Bacteriology
|May 1, 1975
Summary
Hycanthone methanesulfonate (HCT) is a mutagen that causes mutations in bacteria, with its activity dependent on concentration and time. Structure-activity relationship studies indicate specific chemical groups are critical for its mutagenic effects.
Area of Science:
- Microbiology
- Genetics
- Toxicology
Background:
- Hycanthone methanesulfonate (HCT) is known to interact with DNA.
- Understanding the mutagenic potential of HCT is crucial for assessing its safety and developing related compounds.
Purpose of the Study:
- To investigate the mutagenic effects of Hycanthone methanesulfonate (HCT) in bacterial models.
- To determine the structure-activity relationships governing HCT's mutagenicity.
- To compare the mutagenic potency of HCT with known frame-shift mutagens.
Main Methods:
- Bacterial mutagenicity assays using Salmonella typhimurium and Escherichia coli.
- Concentration and time-dependency studies of HCT's mutagenic effects on S. typhimurium TA1532.
- Comparative analysis of mutagenic potency with quinacrine and ICR-191.
- Synthesis and testing of HCT analogues with modifications to ring A and the side chain.
Main Results:
- HCT induced both forward and reverse mutations in S. typhimurium and E. coli.
- Mutagenic effects were concentration and time-dependent.
- The substituent at the 4-position of ring A was critical; hydroxymethyl and aldehyde groups conferred activity, while carboxyl and methyl groups did not.
- Desethyl HCT showed equal mutagenic potency to HCT, indicating the ethyl group is not essential.
- HCT sulfoxide showed marginal activity, likely due to trace HCT contamination; an N-oxide analogue was inactive.
Conclusions:
- Hycanthone methanesulfonate is a potent bacterial mutagen.
- Specific structural features, particularly the substituent at the 4-position of ring A, are essential for HCT's mutagenic activity.
- Further research into HCT analogues could inform the development of safer or more potent therapeutic agents.